Community Academic Profiles
View Larger

Stanley N. Cohen, MD

Academic Appointments

Professional Snapshot

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Consulting:Charter Life Sciences, FivePrime Therapeutics, Functional Genetics, Intercell Therapuetics
Equity:Charter Life Sciences, Functional Genetics
Service on Board of Directors:Functional Genetics

Scientific Focus

Research Interests

Certain of our investigations are aimed at elucidating the signals that govern RNA decay. We use E. coli to investigate the mechanism of action of specific ribonucleases and related proteins, and to identify RNA substrate signals that govern stability. We are also interested in the developmental aspects of RNA stability, and study mechanisms that lead to changes in decay during morphological and biochemical differentiation in the developmentally complex bacterial genus, Streptomyces. Recently, we have begun to use a novel approach, random homozygous knockout (RHKO; see below), to identify components of RNA decay pathways in eukaryotic cells.

Our lab has long been interested in the mechanisms that lead to the evolution and dissemination of antibiotic resistance, and currently, we continue to pursue these interests by investigating the biology of linear plasmids of Streptomyces. In particular, we are interested in the mechanisms by which these plasmids interact with chromosomes to acquire and transfer genes, how plasmids evolve and undergo alterations in structure and how their telomeres function to facilitate these events and propagate plasmid DNA. Studies using DNA microarrays are aimed directly at understanding genetic pathways that regulate antibiotic production and resistance.

Some members of our lab use RHKO (random homozygous knockout) and related approaches, together with DNA microarray analysis, to investigate processes that limit the growth of mammalian cells. RHKO, a genetic method we developed to inactivate mammalian cell genes randomly and homozygously, enables the identification of genes whose loss of function leads to altered growth properties. The TSG101 gene, which was the first gene we identified using RHKO, has now been found to affect endocytic processes as well as established pathways that regulate cell division, and remains an important subject of study in our lab.

A small bioinformatics team within our research group has...

Stanford Medicine Resources:

Footer Links: